IP-10 as a Screening Tool to Optimize HIV Viral Load Monitoring in Resource-limited Settings
暂无分享,去创建一个
J. Blanco | J. Carrillo | D. Naniche | C. Jairoce | M. Rupérez | A. Casellas | Sónia Maculuve | Lucía Pastor | Aina Casellas
[1] F. Barré-Sinoussi,et al. Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset , 2016, PLoS pathogens.
[2] P. Newton,et al. Modelling the Impact and Cost-Effectiveness of Biomarker Tests as Compared with Pathogen-Specific Diagnostics in the Management of Undifferentiated Fever in Remote Tropical Settings , 2016, PloS one.
[3] K. Bonner,et al. Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] C. Ignacio,et al. Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in HIV-Infected Patients in Mozambique , 2015, Journal of acquired immune deficiency syndromes.
[5] R. Paredes,et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. , 2015, The Journal of antimicrobial chemotherapy.
[6] F. Cowan,et al. Finger Prick Dried Blood Spots for HIV Viral Load Measurement in Field Conditions in Zimbabwe , 2015, PloS one.
[7] J. Assmus,et al. IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. , 2015, The Journal of infection.
[8] D. Richman,et al. Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals , 2014, PloS one.
[9] G. Carcelain,et al. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study , 2014, BMC Infectious Diseases.
[10] W. Preiser,et al. Pooled HIV-1 Viral Load Testing Using Dried Blood Spots to Reduce the Cost of Monitoring Antiretroviral Treatment in a Resource-Limited Setting , 2013, Journal of acquired immune deficiency syndromes.
[11] F. Barré-Sinoussi,et al. Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection , 2012, PloS one.
[12] B. Greijdanus,et al. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Linezolid in Patients with Multidrug-Resistant Tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.
[13] Hao Wu,et al. Plasma IP-10 is associated with rapid disease progression in early HIV-1 infection. , 2012, Viral immunology.
[14] P. Ravn,et al. A Simple Method to Quantitate IP-10 in Dried Blood and Plasma Spots , 2012, PloS one.
[15] Beth Chaplin,et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] B. Chi,et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa , 2011, AIDS.
[17] T. F. Rinke de Wit,et al. Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa , 2011, Journal of acquired immune deficiency syndromes.
[18] J. Hibbert,et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications , 2011, Cytokine & growth factor reviews.
[19] Guido Ferrari,et al. Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy , 2011, PloS one.
[20] C. Williamson,et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression , 2010, AIDS.
[21] L. Lynen,et al. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings , 2010, Current opinion in HIV and AIDS.
[22] Mila Lebedeva,et al. Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections , 2009, Journal of Virology.
[23] A. Neumann,et al. IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection , 2006, Hepatology.